Unknown

Dataset Information

0

Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.


ABSTRACT: Human leukocyte antigen (HLA)-independent, T cell-mediated targeting of cancer cells would allow immune destruction of malignancies in all individuals. Here, we use genome-wide CRISPR-Cas9 screening to establish that a T cell receptor (TCR) recognized and killed most human cancer types via the monomorphic MHC class I-related protein, MR1, while remaining inert to noncancerous cells. Unlike mucosal-associated invariant T cells, recognition of target cells by the TCR was independent of bacterial loading. Furthermore, concentration-dependent addition of vitamin B-related metabolite ligands of MR1 reduced TCR recognition of cancer cells, suggesting that recognition occurred via sensing of the cancer metabolome. An MR1-restricted T cell clone mediated in vivo regression of leukemia and conferred enhanced survival of NSG mice. TCR transfer to T cells of patients enabled killing of autologous and nonautologous melanoma. These findings offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies.

SUBMITTER: Crowther MD 

PROVIDER: S-EPMC6983325 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC4990709 | BioStudies
2020-01-01 | S-EPMC7464881 | BioStudies
2018-01-01 | S-EPMC7085347 | BioStudies
2013-01-01 | S-EPMC3651419 | BioStudies
2019-01-01 | S-EPMC6529461 | BioStudies
2020-01-01 | S-EPMC7280785 | BioStudies
2012-01-01 | S-EPMC3328369 | BioStudies
2020-01-01 | S-EPMC7482426 | BioStudies
2013-01-01 | S-EPMC3544856 | BioStudies
2016-01-01 | S-EPMC4947828 | BioStudies